A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Фаза 1/2
Прекращено
NCT05949632
| Заболевание | Advanced Solid Tumors |
|---|
| Фаза | Фаза 1/2 |
|---|
| Спонсор | Incyte Corporation |
|---|
| Статус | Прекращено |
|---|
| Участники | 5 участн. |
|---|
| Вмешательство | INCB099280, axitinib |
|---|
| Дата начала | 16.04.2024 |
|---|
| Дата завершения | 6.06.2025 |
|---|
| Публикация результатов | 4.06.2026 |
|---|
Кратко
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
up to 3 weeks · Participants
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 1 Participants |
|---|
Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
up to approximately 1 year · Participants
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 5 Participants |
|---|
Part 1: Number of Participants With TEAEs Leading to a Dosing Modification (Treatment Interruption, Dose Reduction, and Permanent Discontinuation of Either Study Drug)
up to approximately 1 year · Participants
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 5 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 0 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 4 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 3 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 1 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.